Non-ST-elevation acute coronary syndromes. From clinical trials, to guidelines, to clinical practice in Italy: The need to close the circle;Sindromi coronariche acute senza sopraslivellamento del tratto ST. Dai trial clinici, alle linee guida, alla pratica clinica in Italia: Necessità di chiudere il cerchio

Italian Heart Journal, Supplementi

Volumn 5, Issue 3, 2004, Pages 167-176

  Savonitto, Stefano ^a   Klugmann, Silvio ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Guidelines; Registries

Indexed keywords

ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; FIBRINOGEN RECEPTOR;

ACUTE DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; EVIDENCE BASED MEDICINE; HEART CATHETERIZATION; HEART MUSCLE REVASCULARIZATION; HUMAN; ITALY; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REGISTER; REVIEW; RISK REDUCTION; STATISTICS;

ACUTE DISEASE; CARDIOVASCULAR AGENTS; COMBINED MODALITY THERAPY; CORONARY DISEASE; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HEART CATHETERIZATION; HUMANS; ITALY; MYOCARDIAL REVASCULARIZATION; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; REGISTRIES; RISK REDUCTION BEHAVIOR;

EID: 3042842773     PISSN: 15903796     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997; 349: 1269-76.
2. Braunwald E. Shattuck lecture. Cardiovascular medicine at the turn of the millennium: triumphs, concerns and opportunities. N Engl J Med 1997; 337: 1360-9. (Pubitemid 27467771)
3. Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980-1990: the effect of secular trends in risk factors and treatment. JAMA 1997; 277: 535-42.
4. Lenfant C. Shattuck lecture. Clinical research to clinical practice: lost in translation? N Engl J Med 2003; 349: 868-74.
5. Califf RM, DeMets DL. Principles from clinical trials relevant to clinical practice. Part I. Circulation 2002; 106: 1015-21.
6. Di Chiara A, Chiarella F, Savonitto S, et al, on behalf of the BLITZ Investigators. Epidemiology of acute myocardial infarction in the Italian CCU network. The BLITZ study. Eur Heart J 2003; 24: 1616-29.
7. Tavazzi L, Chiariello M, Scherillo M, et al. Federazione Italiana di Cardiologia (ANMCO/SIC). Documento di Consenso. Infarto miocardico acuto con ST elevato persistente: verso un appropriato percorso diagnostico-terapeutico nella comunità. Ital Heart J Suppl 2002; 3: 1127-64.
8. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281: 707-13.
9. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000; 36: 970-1062.
10. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406-32.
11. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-69.
12. Anderson HV, Gibson RS, Stone PH, et al. Management of unstable angina and non-Q-wave acute myocardial infarction in the United States and Canada (the TIMI III Registry). Am J Cardiol 1997; 79: 1441-6.
13. Yusuf S, Flather M, Pogue J, et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. Lancet 1998; 352: 507-14.
14. Fox KA, Cokkinos DV, Deckers J, Keil U, Maggioni A, Steg G. The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment. Eur Heart J 2000; 21: 1440-9.
15. Collinson J, Flather MD, Fox KA, et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation. Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J 2000; 21: 1450-7.
16. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. (Pubitemid 35215244)
17. Hasdai D, Behar S, Wallentin L, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002; 23: 1190-201.
18. The Registro Osservazionale Agina Instabile (ROSAI-2) Investigators. Treatment of modalities of non-ST-elevation acute coronary syndromes in the real world. Results of the prospective ROSAI-2 registry. Ital Heart J 2003; 4: 782-90.
19. Pavesi PC, Ottani F, Bologna F, Gaddi O, Alboni P, Galvani M, a nome dei Ricercatori dello Studio AI-CARE2. Epidemiologia delle sindromi coronariche acute nelle cardiologie dell'Emilia Romagna: lo studio AI-CARE2. Ital Heart J Suppl 2003; 4: 733-44.
20. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI. A method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-42.
21. Peterson ED, Pollack CV Jr, Roe MT, et al, for the National Registry of Myocardial Infarction (NRMI) 4 Investigators. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction. Observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol 2003; 42: 45-53.
22. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Fragmin and Fast Revascularization during InStability in Coronary artery disease: FRISC II prospective randomized multicentre study. Lancet 1999; 354: 708-15.
23. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. N Engl J Med 1996; 335: 775-82.
24. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
25. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study Investigators. N Engl J Med 1998; 338: 1488-97.
26. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
27. Global Organization Network (PARAGON)-B Investigators. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndrome. Circulation 2002; 105: 316-21.
28. Simoons ML, for the GUSTO IV-ACS Investigators. Effects of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915-24.
29. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994; 89: 1545-56.
30. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998; 338: 1785-92.
31. Cannon CP, Weintraub WS, Demopoulos LA, et al, for the TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)-Thrombolysis in Myocardial Infarction 18 Investigators. Comparison or early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-87.
32. Priori SG, Klein W, Bassand JP, for the ESC committee for practice guidelines 2002-2004; ESC committee for practice guidelines 2000-2002; European Society of Cardiology 2002-2004. Medical practice guidelines. Separating science from economics. Eur Heart J 2003; 24: 1962-4.
33. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med 1989; 321: 1306-11. (Pubitemid 19267218)
34. Woolf SH. Practice guidelines: a new reality in medicine. III. Impact on patient care. Arch Intern Med 1993; 153: 2646-55.
35. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282: 1458-65.
36. Smith R. Medical journals and pharmaceutical companies: uneasy bedfellows. BMJ 2003; 326: 1202-5.
37. Bertrand ME, Simoons ML, Fox KA, et al, for the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40.
38. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina non-ST-segment elevation myocardial infarction - 2000: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 2002; 106: 1893-900.
39. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Lancet 1996; 347: 561-8.
40. Klein W, Buchwald A, Hillis WS, et al. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease. Am J Cardiol 1997; 80: 30E-34E.
41. Montalescot G. New antithrombotic agents in coronary disease. Rev Med Interne 1997; 18: 450-9. (Pubitemid 27288288)
42. Karvouni E, Katritsis D, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003; 41: 26-32. (Pubitemid 36044399)
43. Alexander JH, Sparapani RA, Mahaffey KW, et al. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. JAMA 2000; 283: 347-53.
44. Savonitto S, Granger CB, Ardissino D, et al, for the GUSTO-IIb Investigators. The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. J Am Coll Cardiol 2002; 39: 22-9.
45. Cavallini C, Savonitto S, Violini R, et al, on behalf of the CK-MB and PCI Investigators. Influence of the elevations of the biochemical markers of myocardial damage on long-term mortality after percutaneous coronary revascularisation. In press.
46. Akkerhuis M, Alexander JH, Tardiff BE, et al. Minor myocardial damage and prognosis. Are spontaneous and percutaneous coronary intervention-related events different? Circulation 2002; 105: 554-6.
47. Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and long-term impact of myonecrosis after coronary stenting. Eur Heart J 2002; 23: 869-76. (Pubitemid 34717422)
48. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002; 113: 1-6.
49. Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment ("coolingoff" strategy) before intervention in patients with unstable coronary syndromes. A randomized controlled trial. JAMA 2003; 290: 1593-9.
50. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during InStability in Coronary artery disease. Lancet 2000; 356: 9-16.
51. Fox KA, Poole-Wilson PA, Henderson RA, et al, for the Randomized Intervention Trial of unstable Angina Investigators. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002; 360: 743-51.
52. Maggioni AP, Schweiger C, Tavazzi L, et al. Epidemiologic study of use of resources in patients with unstable angina: the EARISA registry. On behalf on the EARISA Investigators (Epidemiologia dell'Assorbimento di Risorse nell'Ischemia, Scompenso e Angina). Am Heart J 2000; 140: 253-63.
53. Federazione Italiana di Cardiologia. Struttura e organizzazione funzionale della cardiologia. Appendice A. Dati epidemiologici di riferimento. Ital Heart J Suppl 2003; 4: 893-903.
54. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001; 37: 2215-39.
55. Figueras A, Laporte JR. Failures of the therapeutic chain as a cause of drug ineffectiveness. BMJ 2003; 326: 895-6. (Pubitemid 36528943)
56. Savonitto S, Fusco R, Granger CB, et al. Clinical, electrocardiographic, and biochemical data for immediate risk stratification in acute coronary syndromes. Ann Noninvasive Electrocardiol 2001; 6: 64-77. (Pubitemid 32147714)